BioCentury | Apr 7, 2021
Deals

Radioligand target deal with Novartis expands Artios’ runway and remit

Synthetic lethality company Artios is the latest beneficiary of Novartis’ push toward radiotherapeutics, with the pharma paying $20 million up front for rights to three targets to be discovered by the biotech for use in...
BioCentury | Apr 3, 2021
Deals

April 2 Quick Takes: Agios begins share buybacks upon closing Servier deal, plus Royalty-GSK, Gracell-Lonza, Alloy, Eloxx-Zikani and Angelini-Ovid

Upon completing the sale of its cancer business to Servier for $1.8 billion up front and up to $200 million in milestones, Agios Therapeutics Inc. (NASDAQ:AGIO) announced plans to repurchase 7.1 million shares, or $344.5...
BioCentury | Mar 25, 2021
Management Tracks

Galapagos promotes Filius to president, Litchfield named Merck CFO; plus moves at LianBio, Adverum, Fulcrum, Aptose, Cyclerion, Medigene, Apie and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Bart Filius to president from CFO while remaining COO. CEO Onno van de Stolpe will be responsible for oversight of R&D activities. Caroline Litchfield will succeed Robert Davis as CFO of Merck...
BioCentury | Mar 17, 2021
Product Development

March 17 Quick Takes: FDA extends review of Rinvoq in psoriatic arthritis; plus Merck, PharmaEssentia, Lilly, Roche and more

AbbVie Inc. (NYSE:ABBV) said FDA extended by three months its review of an sNDA for Rinvoq upadacitinib to treat adult patients with active psoriatic arthritis after the agency had requested additional information on the oral...
BioCentury | Feb 18, 2021
Finance

Eyeing functional cure, Excision raises $60M to advance CRISPR-based HIV program into Phase I/II

With primate data in hand for its CRISPR-based HIV therapy, Excision raised a $60 million round to advance into the clinic this year.  Antiretroviral therapy (ART) has succeeded in controlling HIV infection by blocking replication,...
BioCentury | Feb 2, 2021
Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

Immunovant Inc. (NASDAQ:IMVT) lost 42% to $25.08 on Tuesday after announcing it was pausing trials of anti-FCRN mAb IMVT-1401 (batoclimab) due to elevated total cholesterol and LDL signals in the Phase IIb ASCEND GO-2 thyroid...
BioCentury | Jan 29, 2021
Management Tracks

Kirk Raab, first BIO chair and early Genentech CEO, dies at 85

...Germany, he graduated with honors in Fine Arts...
BioCentury | Jan 24, 2021
Regulation

Lupus nephritis patients gain oral option as FDA approves Aurinia’s Lupkynis

FDA’s approval Friday of Lupkynis voclosporin will allow Aurinia to introduce an oral therapy into a new marketplace for drugs to treat lupus nephritis, for which there had been no approved treatments before last month’s...
BioCentury | Jan 20, 2021
Product Development

RA readout drives Aclaris’ first big gain since shifting focus to innovative immunology pipeline

An efficacy readout in a small Phase IIa trial of Aclaris’ oral therapy for rheumatoid arthritis has more than tripled the company’s market cap, representing its first major value-creating event since it restructured in 2H19...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

The debut of two more venture-backed companies developing early cancer detection tests suggests there is still appetite for new approaches, even as bigger players consolidate via M&A and prepare for commercial launch. Delfi Diagnostics Inc....
Items per page:
1 - 10 of 12901